Examkin

Question

Difficulty: MediumBias, Confounding, and Validity

A clinical trial data registry is analyzed to assess the effectiveness of a monoclonal antibody directed against calcitonin gene-related peptide (CGRP) versus standard oral prophylactics in patients with chronic migraine. The primary endpoint is the attainment of a ≥50%\geq 50\% reduction in monthly migraine days over a 6-month period.

An initial crude analysis of the entire cohort shows that patients receiving the CGRP monoclonal antibody are more likely to achieve the primary endpoint than those on standard therapy, with a relative risk (RR) of 1.51.5 (95% CI: 1.2−1.81.2 - 1.8).

To further evaluate the data, the researchers stratify the patient population based on the presence of comorbid fibromyalgia. The stratified analysis reveals an RR of 2.62.6 (95% CI: 2.1−3.22.1 - 3.2) in patients with fibromyalgia and an RR of 1.01.0 (95% CI: 0.8−1.20.8 - 1.2) in patients without fibromyalgia.

Based on these statistical findings, which of the following best describes the epidemiological role of comorbid fibromyalgia in this study?

  1. Effect modifierAnswer
  2. B
    Confounding variable
  3. C
    Factor altering positive predictive value
  4. D
    Variable necessitating an alternate statistical test
  5. E
    Source of cognitive bias

Answer

Effect modifier
The correct answer identifies the variable as an effect modifier. In epidemiological studies, stratification is used to distinguish between confounding and effect modification. When the cohort is stratified by a third variable (fibromyalgia) and the resulting measure of association (relative risk) is significantly different between the strata (2.6 vs. 1.0), the third variable is an effect modifier. This means the therapeutic impact of the CGRP monoclonal antibody genuinely differs depending on whether a patient has comorbid fibromyalgia. Effect modification is a biological phenomenon to be reported, not a bias to be mathematically eliminated.

Step-by-Step Solution

1
Identify the initial relationship between exposure and outcome.
The crude relative risk of the CGRP antibody versus standard therapy is 1.5, suggesting an overall benefit.
Establishing the baseline crude effect size is necessary before evaluating the impact of stratification.
2
Analyze the relationship after stratification by the third variable (fibromyalgia).
The relative risk in the fibromyalgia group is 2.6, while the relative risk in the non-fibromyalgia group is 1.0.
Stratification is the definitive epidemiological method for distinguishing between confounding and effect modification.
3
Compare the stratum-specific relative risks to each other.
The relative risks (2.6 and 1.0) are significantly different from one another.
When stratum-specific relative risks differ significantly from each other, it demonstrates that the third variable modifies the magnitude of the exposure's effect on the outcome, which defines effect modification.

Key Concept

Effect modification occurs when the magnitude or direction of an exposure's effect on an outcome varies depending on the level of a third variable. It is distinguished from confounding by performing a stratified analysis: if the stratum-specific relative risks are significantly different from one another, the third variable is an effect modifier.
Rate this question

Topics

Bias, Confounding, and Validity

More questions from this topic